Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis-Reference-Cited by-同舟云学术

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

Published:2014-03 Issue:2 Volume:15 Page:110-118
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Simos Demetrios,Sajjady Golmehr,Sergi Melissa,Liew Mun Sem,Califano Raffaele,Ho Cheryl,Leighl Natasha,White Shane,Summers Yvonne,Petrcich William,Wheatley-Price Paul

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Small cell lung cancer: have we made progress over the last 25 years?;Lally;Oncologist,2007

2. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline;Cheng;J Thor Oncol,2007

3. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

4. Gender and histologic type variations in smoking-related risk of lung cancer;Brownson;Epidemiology,1992

5. Emerging drugs for small-cell lung cancer;Metro;Expert Opin Emerg Drugs,2009

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study;Lung Cancer;2024-07

2. The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study;Translational Lung Cancer Research;2024-06

3. CACA guidelines for holistic integrative management of lung cancer;Holistic Integrative Oncology;2024-03-08

4. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202);Frontiers of Medicine;2022-07-16

5. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study;British Journal of Cancer;2021-05-18